• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

10 Juicy Facts About Apples

Slideshow

About that apple-a-day-is there proof it keeps the doctor away? Find out in this slide-show summary of some well-known, and lesser-known, facts about apples and good health.

 Does an apple a day really keep the doctor away? A number of well-conducted studies support both well-known, and lesser-known, health benefits of the autumnal fruit, from antioxidant effects and cancer prevention to mood elevation in dementia. But one study, described later in this slideshow, reveals findings on the subject that might surprise you.Above find brief summaries of some of the newer science behind the old adage and polish up this traditional heart-healthy Rx. 

References:

1. Comparing Apples and Oranges, and Bananas

2. Core Components

3. Apples, Gut Microbes, and Cardiovascular Health

4. Antioxidants in Apples vs Cancer

5. Study: Apples Lower Type 2 Diabetes Risk

6. Potassium Protects Heart, Bones, and Muscles

7. Apple Juice Ups Mood in Alzheimer

8. Appeal of the Peel: Please Eat!

9. Just Desserts: Apple vs Chocolate Bar

10. ALERT: Does Apple a Day Really Keep Doc Away?

 

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Grace Halsey
November 21st 2024
Article

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose

Sydney Jennings
November 14th 2024
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Grace Halsey
November 7th 2024
Article

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity / Image credit: ©missbobbit/AdobeStock

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity

Sydney Jennings
November 6th 2024
Article

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

© 2024 MJH Life Sciences

All rights reserved.